Overview

* Krystal Biotech Q3 2025 product revenue rises to $97.8 mln, up from $83.8 mln in 2024

* Net income for Q3 2025 increases to $79.4 mln from $27.2 mln in 2024

* Company launched VYJUVEK in Germany in Q3, France and Japan in Q4

Outlook

* Company expects cystic fibrosis interim data readout in Q4 2025

* Krystal Biotech ( KRYS ) anticipates pricing negotiations in Germany to continue until at least 2H 2026

* Company projects non-GAAP R&D and SG&A expenses between $145 mln and $155 mln for FY 2025

Result Drivers

* VYJUVEK LAUNCHES - Launched in Germany, contributing to revenue growth

* EXPANDED LABEL - FDA approval expanded VYJUVEK's eligible patient population in the U.S.

* HIGH GROSS MARGIN - Achieved a gross margin of 96% for the quarter

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $97.80

Product mln

Revenue

Q3 Net $79.36

Income mln

Q3 $56.42

Operatin mln

g

Expenses

Q3 $41.37

Operatin mln

g Income

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)